Chimeric Therapeutics (ASX:CHM) Interest Expense : A$-1.10 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Chimeric Therapeutics's interest expense for the six months ended in Dec. 2023 was A$ -0.33 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Chimeric Therapeutics's Operating Income for the six months ended in Dec. 2023 was A$ -9.04 Mil. Chimeric Therapeutics's Interest Expense for the six months ended in Dec. 2023 was A$ -0.33 Mil. Chimeric Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chimeric Therapeutics Interest Expense Historical Data

The historical data trend for Chimeric Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Interest Expense Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Interest Expense

-0.01

-0.64

-0.77

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial			-0.15	-0.49	-0.01	-0.76	-0.33

Chimeric Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.10 Mil.

Chimeric Therapeutics (ASX:CHM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chimeric Therapeutics's Interest Expense for the six months ended in Dec. 2023 was A$-0.33 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-9.04 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was A$0.00 Mil.

Chimeric Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Chimeric Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines